- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03912012
Pilot Study DiaDEP (DiaDEP)
Endothelial Dysfunction Could be an Early Biomarker of Renal Impairment in Children and Adolescent With Type 1 Diabetes. Pilot Study DiaDEP
With an increased incidence of pediatric type 1 diabetes (T1D) and a decrease in age at diagnosis, children are exposed to complications such as renal impairment at a very young age.
The current biomarker used to diagnose renal impairment is microalbuminuria, but it's a late marker. Early screening is a major issue to reduce T1D consequences.
Early glomerular hyperfiltration (GHF) could participate in the development and progression of nephropathy. Hyperfiltration has also been associated with a systemic endothelial dysfunction and with changes in arterial stiffness, suggesting, at least to a certain extent, a state of generalized vascular dysfunction.
Diabetes is responsible for very early neurovascular dysfunctions, detectable with techniques to evaluate cutaneous neurovascular interaction. Those should help bringing to light very early microcirculation impairment, particularly precocious endothelial dysfunction (ED).
No study about correlation between GHF and ED is currently available. The hypothesis assessed is those of a strong correlation between ED and GHF in children and adolescent with a story of T1D for at least 10 years.
This pilot study should allow assessing ED's and GHF's proportions in our population, in order to conduct a larger study to prove, in a prospective way, the prognostic value of ED in the apparition of nephropathy, taking into count other factors such as diabetes duration or stability.
This measure could be included in the global evaluation of microangiopathy risk in children and then take action to prevent negative outcomes.
The second aspect of this study is the assessment of other functions and metabolisms possibly impaired in T1D: osseous microarchitecture, vitamin D status and precocious evaluation of macro angiopathy through intima media thickness measurement.
Long term diabetes in children is associated with shorter and leaner bones, despite a correct mineralization, a reduced bone density and a fracture risk increased six fold. Bone status in the population will be evaluated through the study of bones microarchitecture via HR-pQCT (High Resolution peripheral Quantitative Computed Tomography) on both tibia and radius, dual-energy X-ray absorptiometry (DXA), and bone turn over biochemical markers.
Results on bone microarchitecture in a preexisting cohort of healthy children and adolescents will be used to compare results.
Study Overview
Status
Conditions
Intervention / Treatment
- Drug: Iohexol renal clearance measurement
- Device: microcirculation assessment through Laser Doppler associated to iontophoresis.
- Device: Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement
- Biological: Blood sampling
- Biological: Urine sampling
- Device: High-resolution peripheral quantitative computed tomography (HR-pQCT)
- Radiation: Dual-energy X-ray (DXA)
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bron, France, 69677
- Hopital Femme Mère Enfant - Groupement Hospitalier Est
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged ≥ 10 et < 18 years old
- Type 1 diabetes diagnosed more than 10 years previously.
- Written informed consent signed by both parents or legal representatives, child or adolescent's agreement.
- Health cover
Exclusion Criteria:
- Associated pathology with a potential impact on cutaneous microcirculation or renal function.
- Aspirin or other non-steroid anti-inflammatory treatment with potential impact on endothelial function in the 3 weeks preceding the visit.
- Examination with injection of contrast agent during the last 48 hours
- Smoking
- Ongoing pregnancy or breast feeding
- Hypersensitivity to acetylcholine
- Contraindication to Iohexol
- Ongoing treatment with growth hormone, non-inhaled corticosteroids or anti-calcineurins;
- History of treatment with oral corticosteroids (not inhaled) more than 3 successive months regardless of seniority;
- Paracetamol treatment less than a week old;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Children and adolescent with a history of type 1 diabetes
Children and adolescent from 10 to 18 years old, with a history of type 1 diabetes for at least 10 years.
Glomerular hyper filtration and endothelial dysfunction will be evaluate.
|
intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.
endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
carotid ultrasound (during Day 1)
37 mL of blood sample will be performed at Day 1
The urinary collection will be done during the Day 1, on the first morning urination
assessment of the Body Mass Index by HR-pQCT (during the Day 1)
assessment of bone parameters by DXA (during the Day 1)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glomerular hyper filtration (Glomerular filtration > 135 mL/min/1,73 m2)
Time Frame: Day 1
|
assessed through Iohexol renal clearance measurement
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endothelial function in the forearm.
Time Frame: Day 1
|
Endothelial function will be evaluated by the microcirculation assessment through Laser Doppler associated to iontophoresis of acetylcholine.
|
Day 1
|
Intima media thickness
Time Frame: Day 1
|
The intima media thickness will be performed by Echo Doppler of both right and left common carotid
|
Day 1
|
arterial blood pressure
Time Frame: Day 1
|
arterial blood pressure measurement
|
Day 1
|
Bone mass
Time Frame: Day 1
|
Bone mass will be performed by Dual-energy X-ray absorptiometry (DXA) on both spine and whole body.
|
Day 1
|
bone density
Time Frame: Day 1
|
bone density will be performed by Dual-energy X-ray absorptiometry (DXA) on both spine and whole body.
|
Day 1
|
quantization of bone mineral content
Time Frame: Day 1
|
quantization of bone mineral content will be performed by Dual-energy X-ray absorptiometry (DXA) on both spine and whole body.
|
Day 1
|
Volumetric compartmental density
Time Frame: Day 1
|
Volumetric compartmental density will be performed by High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) on radius and tibia (Right tibia and non-dominant arm radius).
(Unless there is a history of fracture for one of those bones, in which case the opposite side will be studied instead.)
|
Day 1
|
trabecular microarchitecture
Time Frame: Day 1
|
trabecular microarchitecture will be performed by High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) on radius and tibia (Right tibia and non-dominant arm radius).
(Unless there is a history of fracture for one of those bones, in which case the opposite side will be studied instead.)
|
Day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL17_0518
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Iohexol renal clearance measurement
-
University of NottinghamUnknown
-
Thomas MuellerUnknownKidney Neoplasms | Adult Polycystic Kidney Disease | Kidney DysfunctionSwitzerland
-
Quark PharmaceuticalsTerminatedCardiac SurgeryUnited States
-
University of Colorado, DenverRecruitingKidney Diseases | Kidney Injury | TransgenderismUnited States
-
Universitaire Ziekenhuizen KU LeuvenCompletedPrevalence of Augmented Renal Clearance | Risk Factors for Augmented Renal ClearanceBelgium
-
Central Hospital, Nancy, FranceRecruiting
-
Nicole LindenblattUniversity Hospital, Zürich; Swiss Federal Institute of Technology; Zurich University... and other collaboratorsCompletedLymphedema | Secondary LymphedemaSwitzerland
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
The HIV Netherlands Australia Thailand Research...Chulalongkorn University; Kirby InstituteCompletedHIV Infection | Renal FunctionThailand
-
University Hospital, GhentCompletedCritical Illness | Renal FunctionBelgium